Drug details

Sotyktu (deucravacitinib tablets)

type of Antineoplastic Tyrosine Kinase Inhibitors

Sotyktu (deucravacitinib) is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• fever,
• tiredness,
• dark colored urine,
• muscle weakness
• muscle pain or tenderness, and

The following drugs are related to Sotyktu, either as a replacement or used together:

• Humira (adalimumab injection solution for subcutaneous administration)
• Otezla (apremilast tablets)
• Avsola (infliximab-axxq for injection)
• Bryhali (halobetasol propionate lotion)
• Cosentyx (secukinumab injection)
• Eucrisa Ointment (crisaborole)
• Duobrii (halobetasol propionate and tazarotene lotion)
• Elidel (pimecrolimus cream)
• Elocon (mometasone furoate)
• Elocon Lotion (mometasone furoate lotion)
• Elocon Ointment (mometasone furoate ointment)
• Enbrel (etanercept)
• Tremfya (guselkumab for injection)
• Inflectra (infliximab-dyyb intravenous injection)
• Remicade (infliximab)
• Renflexis (infliximab-abda injection)
• Taltz (ixekizumab injection, for subcutaneous use)
• Skyrizi (risankizumab-rzaa injection)
• Stelara Injection (ustekinumab)